EZH2 and cancer: Indeed, as EZH2 can promote cancer independently of its methyltransferase activity [25] or by acting as a transcriptional coactivator [26–28], targeting EZH2 abundance may be more effective than enzymatic EZH2 inhibition against cancers that are driven by EZH2 methyltransferase-independent mechanisms.